Rousselot leads on innovation at CPhI

Son, Netherlands – 23 August 2018 - Rousselot^®, leading global producer of gelatin and collagen peptides , focuses on highlighting its unrivalled portfolio of premium gelatins for advanced pharma and biomedical applications at this year’s CPhI Worldwide. At bioLIVE stand #12B13, Rousselot will present its medical grade gelatin range, X-Pure^®, with outstanding levels of purity for in-body applications. Rousselot will be running a number of expert-led talks throughout the show, where attendees can expand their knowledge on the effects of endotoxin. From its nutraceutical product portfolio, Rousselot will present its recently launched Peptan^® IIm, a hydrolyzed collagen type II matrix that specifically targets joint health at a lunch brief and partnering sessions in a dedicated meeting space.

At its booth at the CPhI’s bioLIVE area, Rousselot will introduce its low-endotoxin X-Pure range for the first time to the European market. Advanced gelatins with low endotoxin levels are needed for demanding medical applications including haemostatic medical devices, parenteral formulations and regenerative medicine applications. With endotoxin levels below 100, 20 or 10 Endotoxin Units per gram (EU/g) or even below LAL analysis detection limits², the X-Pure range offers unrivalled levels of safety for all these in-body medical applications.

For regenerative medicine, in particular, Rousselot has developed five X-Pure gelatins to exactly match the needs of diverse final medical applications. These five gelatin grades come with different viscosities, gel strengths and endotoxin levels and bring significant technical advantages for cell growth or cell transportation, tissue engineering or 3D printing for example.